Details for New Drug Application (NDA): 202351
✉ Email this page to a colleague
NDA 202351 describes TOPOTECAN HYDROCHLORIDE, which is a drug marketed by Accord Hlthcare, Actavis Totowa, Dr Reddys Labs Ltd, Fresenius Kabi Usa, Meitheal, Novast Labs, Rising, Sagent Pharms, Sun Pharm Inds Ltd, Teyro Labs, Dash Pharms, and Hospira Inc, and is included in fifteen NDAs. It is available from five suppliers. Additional details are available on the TOPOTECAN HYDROCHLORIDE profile page.
The generic ingredient in TOPOTECAN HYDROCHLORIDE is topotecan hydrochloride. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the topotecan hydrochloride profile page.
The generic ingredient in TOPOTECAN HYDROCHLORIDE is topotecan hydrochloride. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the topotecan hydrochloride profile page.
Summary for 202351
| Tradename: | TOPOTECAN HYDROCHLORIDE |
| Applicant: | Accord Hlthcare |
| Ingredient: | topotecan hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 202351
| Mechanism of Action | Topoisomerase Inhibitors |
Medical Subject Heading (MeSH) Categories for 202351
Suppliers and Packaging for NDA: 202351
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TOPOTECAN HYDROCHLORIDE | topotecan hydrochloride | INJECTABLE;INJECTION | 202351 | ANDA | Accord Healthcare, Inc. | 16729-151 | 16729-151-31 | 1 VIAL in 1 PACKAGE (16729-151-31) / 4 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 4MG BASE/VIAL | ||||
| Approval Date: | Jun 26, 2013 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
